Name:Yechezkel Barenholz

Title： Professor Emeritus of Biochemistry and Daniel G. Miller Professor in Cancer Research

Email: chezyb@ekmd.huji.ac.il; 

            chezyb1@gmail.com

                                           Tel: 972-2-6757615

Research Interests

Professor Barenholz's research activities focused on many research fields related to the biochemistry and biophysics of lipids and membranes, including synthesis, chemical and physical characterization, and the relationship between membrane lipid composition, structure, and function. In many of these projects he used liposomes as a model of biological membranes. In 1980 he started to apply the expertise he gained in his basic research to applied research oriented mainly to the development of drug delivery systems. In this applied research, his main interests have been in amphiphile-based drug carriers, especially liposomes - from basic aspects of design of the drug carrier, through animal studies, to clinical trials, and FDA approval, as exemplified by the development of DOXIL, the first liposomal drug and nano-medicine that was approved by the FDA.

Ten Selected Papers

*co-corresponding authors; #co-first authors

(1) Schilt Y, Berman T, Wei X, Nativ-Roth E, Barenholz Y, Raviv U. Effect of the ammonium salt anion on the structure of doxorubicin complex and PEGylated liposomal doxorubicin nanodrugs. Biochim Biophys Acta Gen Subj 2021;1865(5).

(2) Bavli Y, Rabie M, Fellig Y, Nevo Y, Barenholz Y. Liposomal bupivacaine (Bupigel) demonstrates minimal local nerve toxicity in a rabbit functional model. Pharmaceutics 2021;13(2):1-17.

(3) Nordström R, Zhu L, Härmark J, Levi-Kalisman Y, Koren E, Barenholz Y, et al. Quantitative cryo-tem reveals new structural details of doxil-like pegylated liposomal doxorubicin formulation. Pharmaceutics 2021;13(1):1-19.

(4) Klein Y, Fleissig O, Polak D, Barenholz Y, Mandelboim O, Chaushu S. Immunorthodontics: in vivo gene expression of orthodontic tooth movement. Sci Rep 2020;10(1).

(5) Chen E, Chen B-, Su Y-, Chang Y-, Cheng T-, Barenholz Y, et al. Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex. ACS Nano 2020;14(7):7808-7822.

(6) Bavli Y, Chen B-, Roffler SR, Dobrovolskaia MA, Elnekave E, Ash S, et al. PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A correlation between in vitro immunological and in vivo clinical studies. Molecules 2020;25(3).

(7) Singh MS, Goldsmith M, Thakur K, Chatterjee S, Landesman-Milo D, Levy T, et al. An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. Nanoscale 2020;12(3):1894-1903.

(8) Even-Or O, Avniel-Polak S, Barenholz Y, Nussbaum G. The cationic liposome CCS/C adjuvant induces immunity to influenza independently of the adaptor protein MyD88. Hum Vaccines Immunother 2020;16(12):3146-3154.

(9) Gawne PJ, Clarke F, Turjeman K, Cope AP, Long NJ, Barenholz Y, et al. PET imaging of liposomal glucocorticoids using 89Zr-oxine: Theranostic applications in inflammatory arthritis. Theranostics 2020;10(9):3867-3879.

(10) Goldmann O, Cern A, Muesken M, Rohde M, Weiss W, Barenholz Y, et al. Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections. J Control Release 2019;316:292-301.